BeiGene reports Q3 EPS ($5.39), consensus ($4.01)

Reports Q3 revenue $387.63M, consensus $385.77M. "BeiGene generated strong product revenue in the third quarter, led by growth of our internally developed cornerstone assets, BRUKINSA(R) and tislelizumab, and BRUKINSA has now been approved in more than 55 markets around the world," said John Oyler, co-founder, chairman and CEO of BeiGene. "We are delighted with the recently reported positive topline results from the final progression-free survival analysis of BRUKINSA compared to IMBRUVICA(R), which supports our confidence in BRUKINSA as a potential new treatment that can provide hope for patients and families with CLL. We look forward to sharing the full data with the medical and patient communities, to important milestones in the coming months and to a strong finish for 2022."